# Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

> **NCT01492543** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tegafur Gimeracil Oteracil Potassium Capsule

## Key facts

- **NCT ID:** NCT01492543
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492543, "Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01492543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*